Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Molecule Holdings Inc C.MLCL

Alternate Symbol(s):  EVRRF

Healthcare
Molecule Holdings Inc. is a Canada-based licensed producer engaged in creating cannabis-infused beverages (CIBs) for the Canadian market. The Company operates through one segment being the production and co-packing CIBs. The Company produces drinks to provide opportunity and choice for people seeking a convenient and social way to consume cannabis. Its brands include PHRESH, embody, CANAJO and KLON. It is also focused on growing both its portfolio, and the overall cannabis beverage market.


CSE:MLCL - Post by User

Molecule Holdings Inc > New Data
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(585)
•••
Comment by dart321on Jan 01, 2023 3:50pm
84 Views
Post# 35199076

RE:New Data

RE:New DataThe numbers I post are a reduced number by a certain percentage from what the research was really telling us, it's always better to be low that to high
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities